ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
← catalyst calendarNCT07011706 · readout ≤ 11 d
Sponsored by Aclaris Therapeutics, Inc. (industry) · ACRS — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
110actual
Sites
60
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-30 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis
- Atopic
- Dermatitis
- AD
- Eczema
Interventions
- Drug: ATI-045
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change in Eczema Area and Severity Index (EASI)
measured Baseline to Week 24
Permalink · ACRS's whole pipeline · Catalyst calendar · Every registered study · What changed